Hims & Hers (HIMS) Chief Legal Officer sells 4,812 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton executed an open-market sale of 4,812 shares of Class A common stock at $24.69 per share. After this transaction, she directly holds 308,831 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025, indicating it was scheduled in advance rather than timed opportunistically.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 4,812 shares ($118,808)
Net Sell
1 txn
Insider
Boughton Soleil
Role
Chief Legal Officer
Sold
4,812 shs ($119K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 4,812 | $24.69 | $119K |
Holdings After Transaction:
Class A Common Stock — 308,831 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did Hims & Hers (HIMS) Chief Legal Officer report in this Form 4?
Hims & Hers Chief Legal Officer Soleil Boughton reported an open-market sale of 4,812 Class A common shares at $24.69 each. Following the sale, she directly owns 308,831 shares, according to the filing’s post-transaction ownership disclosure.
Was the Hims & Hers (HIMS) insider sale made under a Rule 10b5-1 trading plan?
Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans pre-schedule trades, reducing the likelihood that the timing reflects short-term views on the stock.
What type of transaction did the Hims & Hers (HIMS) Form 4 disclose?
The Form 4 discloses an open-market sale of Class A common stock, coded “S” for sale. It is a non-derivative transaction, meaning it involved common shares directly rather than options, warrants, or other derivative securities.